Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Last trade$13.23
Day change+$0.465 (+3.64%)
Day range$11.61 – $13.52
Volume521,179
Market cap$450M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$450.49M
Price / earnings
222.25×
Price / book
9.16×
Price / sales
6.79×
EV / sales
6.05×
EV / EBITDA
108.07×
Profitability
Earnings per share
$0.06
Return on assets
2.43%
Return on equity
4.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.11×
Quick ratio
5.95×
Cash ratio
3.68×
Cash flow
Price / cash flow
142.97×
Price / free cash flow
142.97×
Free cash flow
$3.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FENC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$19.61M
$17.87M
$15.11M
$13.78M
$12.46M
$9.65M
$8.75M
$7.93M
Cost of revenue
$838K
$721K
$570K
$1.76M
$660K
$967K
$373K
$669K
Gross profit
$18.77M
$17.15M
$14.54M
$12.01M
$11.8M
$8.69M
$8.38M
$7.26M
Selling, general and administrative
$13.96M
$15.3M
$14.61M
$14.55M
$11.96M
$11.31M
$9.09M
$8.14M
Research and development
$154K
$118K
$49K
$20K
$29K
$107K
$94K
$50K
Total operating expenses
$14.12M
$15.42M
$14.66M
$14.57M
$11.99M
$11.42M
$9.19M
$8.19M
Operating income
$4.65M
$1.74M
-$119K
-$2.55M
-$189K
-$2.73M
-$808K
-$934K
Interest expense
-$1K
-$3K
-$7K
-$308K
-$586K
-$594K
-$592K
-$966K
Income before taxes
$4.97M
$2.02M
$201K
-$4.68M
-$638K
-$3.15M
-$1.17M
-$1.62M
Income taxes
$332K
$42K
$0
$106K
$0
$0
$0
$365K
Net income
$4.64M
$1.97M
$201K
-$4.79M
-$638K
-$3.15M
-$1.17M
-$1.99M
Net income attributable to common shareholders
$4.64M
$1.97M
$201K
-$4.79M
-$638K
-$3.15M
-$1.17M
-$1.99M
EBITDA
$4.65M
$1.74M
-$119K
-$2.55M
-$189K
-$2.73M
-$808K
-$934K
Basic earnings per share
$0.13
$0.06
$0.01
-$0.15
-$0.02
-$0.11
-$0.04
-$0.07
Diluted earnings per share
$0.12
$0.05
$0.01
-$0.15
-$0.02
-$0.11
-$0.04
-$0.08
Recent news
Company coverage with links to the original publishers.
Southpoint Capital Advisors sold 1 million common shares (2.93%) of Fennec Pharmaceuticals on December 24, 2025, at USD $7.50 per share. The firm retains control of 2.7 million shares (approximately 8% of outstanding shares on a fully diluted basis) and may adjust its position based on market conditions.
Fennec Pharmaceuticals plans to raise up to $5,025,000 through a non-brokered offering of common shares in Canada at $7.50 per share, with the offering expected to close on November 17, 2025.
Fennec Pharmaceuticals is conducting a public offering of 4,666,667 common shares at $7.50 per share, expecting to raise approximately $35 million. The proceeds will be used to repurchase debt and for general corporate purposes.
Fennec Pharmaceuticals reported strong Q2 2025 earnings with $9.7 million in net product sales, representing 33% year-over-year growth. The company is expanding internationally through partnerships, securing formulary wins, and preparing for potential milestone events in Europe and Japan.
Fennec Pharmaceuticals reported strong first-quarter 2025 financial results, with total net revenues up 18% year-over-year. The company attributed the positive momentum to its refined sales strategy and enhanced patient support services.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.